The effect of a topical combination of clonidine and pentoxifylline on post-traumatic neuropathic pain patients: study protocol for a randomized, double-blind placebo-controlled trial

Oli Abate Fulas, André Laferrière, D Mark A Ware, Yoram Shir, Terence J Coderre, Oli Abate Fulas, André Laferrière, D Mark A Ware, Yoram Shir, Terence J Coderre

Abstract

Background: First-line pharmacotherapy for neuropathic pain entails the use of systemic antidepressants and anticonvulsants. These drugs are not optimally effective and poorly tolerated, especially for older patients with comorbid conditions. Given the high number of such patients, there is a need for a greater repertoire of safer and more effective analgesics. Clonidine and pentoxifylline are vasodilator agents that work synergistically to enhance tissue perfusion and oxygenation. The topical administration of these drugs, individually and in combination, has shown anti-nociceptive properties in rodent models of neuropathic pain. A topically-administered combination of clonidine and pentoxifylline also effectively reduced the intensity of both spontaneous and evoked pain in healthy volunteers with experimentally-induced neuropathic pain. The next step in advancing this formulation to clinical use is the undertaking of a phase II clinical study to assess its efficacy and safety in neuropathic pain patients.

Methods/design: This is a study protocol for a randomized, double-blind, placebo-controlled, phase II clinical trial with a cross-over design. It is a single-centered, 5-week study that will enroll a total of 32 patients with post-traumatic peripheral neuropathic pain. Patients will be treated topically with either a combination of clonidine and pentoxifylline or placebo for a period of 2 weeks each, in randomly assigned order across patients, with an intervening washout period of 1 week. The primary outcome measures of the study are the intensity of spontaneous pain recorded daily in a pain diary with a visual analog scale, and the degree of mechanical allodynia evoked by a brush stimulus. The secondary outcome measures of the study include scores of pain relief and change in the area of punctate hyperalgesia. This trial has been prospectively registered with ClinicalTrials.gov on November 1, 2017. ClinicalTrials.gov Identifier: NCT03342950 .

Discussion: The analgesic use of topical treatment with clonidine and pentoxifylline in combination has not been investigated in post-traumatic neuropathic pain. This study could generate the first evidence for the efficacy and safety of the formulation in alleviating pain in patients with neuropathic pain. Furthermore, this trial will provide objective grounds for the investigation of other agents that enhance tissue oxygenation in the topical treatment of peripheral neuropathic pain.

Trial registration: This trial has been registered with ClinicalTrials.gov owned by NIH's US National Library of Medicine. ClinicalTrials.gov NCT03342950 . Registered on November 1, 2017 (trial was prospectively registered).

Protocol version and identifiers: This is protocol version 5, dated June 2018. McGill University Health Center (MUHC) Reaseach Ethics Board (REB) identification number: TTNP 2018-3906.

Keywords: Clonidine; Dynamic mechanical allodynia; Pentoxifylline; Post-traumatic peripheral neuropathic pain; Punctate hyperalgesia; Topical treatment.

Conflict of interest statement

The study investigator and team have no competing interests to declare.

Figures

Fig. 1
Fig. 1
Study flow chart

References

    1. Treede RD, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology. 2008;70(18):1630–1635. doi: 10.1212/01.wnl.0000282763.29778.59.
    1. Colloca L, et al. Neuropathic pain. Nat Rev Dis Primers. 2017;3:17002. doi: 10.1038/nrdp.2017.2.
    1. Attal N. Pharmacological treatments of neuropathic pain: the latest recommendations. Rev Neurol (Paris) 2019;175(1–2):46–50. doi: 10.1016/j.neurol.2018.08.005.
    1. Haanpää ML, et al. Treatment considerations for patients with neuropathic pain and other medical comorbidities. Mayo Clin Proc. 2010;85(3 Suppl):S15–S25. doi: 10.4065/mcp.2009.0645.
    1. Schmader KE, et al. Treatment considerations for elderly and frail patients with neuropathic pain. Mayo Clin Proc. 2010;85(3 Suppl):S26–S32. doi: 10.4065/mcp.2009.0646.
    1. Cameron NE, et al. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia. 2001;44(11):1973–1988. doi: 10.1007/s001250100001.
    1. Malik RA, et al. Endoneurial localisation of microvascular damage in human diabetic neuropathy. Diabetologia. 1993;36(5):454–459. doi: 10.1007/BF00402283.
    1. Mackinnon SE, et al. Chronic human nerve compression--a histological assessment. Neuropathol Appl Neurobiol. 1986;12(6):547–565. doi: 10.1111/j.1365-2990.1986.tb00159.x.
    1. Lipowsky HH. Microvascular rheology and hemodynamics. Microcirculation. 2005;12(1):5–15. doi: 10.1080/10739680590894966.
    1. Van Dam PS, et al. Pathogenesis of diabetic neuropathy: focus on neurovascular mechanisms. Eur J Pharmacol. 2013;719(1):180–186.
    1. Cameron NE, Cotter MA. The neurocytokine, interleukin-6, corrects nerve dysfunction in experimental diabetes. Exp Neurol. 2007;207(1):23–29. doi: 10.1016/j.expneurol.2007.05.009.
    1. Bruno RM, et al. Sympathetic regulation of vascular function in health and disease. Front Physiol. 2012;3:284. doi: 10.3389/fphys.2012.00284.
    1. Bauer V, Sotníková R. Nitric oxide—the endothelium-derived relaxing factor and its role in endothelial functions. Gen Physiol Biophys. 2010;29(4):319. doi: 10.4149/gpb_2010_04_319.
    1. Kass DA, et al. Phosphodiesterase regulation of nitric oxide signaling. Cardiovasc Res. 2007;75(2):303–314. doi: 10.1016/j.cardiores.2007.02.031.
    1. Shafiee-Nick R, et al. A comprehensive review on the potential therapeutic benefits of phosphodiesterase inhibitors on cardiovascular diseases. Biomed Pharmacother. 2017;94:541–556. doi: 10.1016/j.biopha.2017.07.084.
    1. McCarty MF, O’Keefe JH, DiNicolantonio JJ. Pentoxifylline for vascular health: a brief review of the literature. Open Heart. 2016;3(1):e000365. doi: 10.1136/openhrt-2015-000365.
    1. Perego MA, et al. Haemorrheological improvement by pentoxifylline in patients with peripheral arterial occlusive disease. Curr Med Res Opin. 1986;10(2):135–138. doi: 10.1185/03007998609110431.
    1. Ott E, Lechner H, Fazekas F. Hemorheological effects of pentoxifylline on disturbed flow behavior of blood in patients with cerebrovascular insufficiency. Eur Neurol. 1983;22(Suppl 1):105–107. doi: 10.1159/000115658.
    1. van Brummelen P, Jie K, van Zwieten PA. Alpha-adrenergic receptors in human blood vessels. Br J Clin Pharmacol. 1986;21(Suppl 1):33s–39s. doi: 10.1111/j.1365-2125.1986.tb02851.x.
    1. Szabo B, Hedler L, Starke K. Peripheral presynaptic and central effects of clonidine, yohimbine and rauwolscine on the sympathetic nervous system in rabbits. Naunyn Schmiedeberg’s Arch Pharmacol. 1989;340(6):648–657. doi: 10.1007/BF00717740.
    1. Figueroa XF, et al. Clonidine-induced nitric oxide-dependent vasorelaxation mediated by endothelial alpha (2)-adrenoceptor activation. Br J Pharmacol. 2001;134(5):957–968. doi: 10.1038/sj.bjp.0704320.
    1. Yagihashi S, Mizukami H, Sugimoto K. Mechanism of diabetic neuropathy: where are we now and where to go? J Diab Investig. 2011;2(1):18–32. doi: 10.1111/j.2040-1124.2010.00070.x.
    1. Dyck PJ, et al. The spatial distribution of fiber loss in diabetic polyneuropathy suggests ischemia. Ann Neurol. 1986;19(5):440–449. doi: 10.1002/ana.410190504.
    1. Peppin JF, et al. Skin matters: a review of topical treatments for chronic pain. Part one: skin physiology and delivery systems. Pain Ther. 2015;4(1):17–32. doi: 10.1007/s40122-015-0031-0.
    1. Ragavendran JV, et al. Topical combinations aimed at treating microvascular dysfunction reduce allodynia in rat models of CRPS-I and neuropathic pain. J Pain. 2013;14(1):66–78. doi: 10.1016/j.jpain.2012.10.004.
    1. Davis K, et al. Topical application of clonidine relieves hyperalgesia in patients with sympathetically maintained pain. Pain. 1991;47(3):309–317. doi: 10.1016/0304-3959(91)90221-I.
    1. Campbell CM, et al. Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy. Pain. 2012;153(9):1815–1823. doi: 10.1016/j.pain.2012.04.014.
    1. Ragavendran JV, et al. Effects of topical combinations of clonidine and pentoxifylline on capsaicin-induced allodynia and postcapsaicin tourniquet-induced pain in healthy volunteers: a double-blind, randomized, controlled study. Pain. 2016;157(10):2366–2374. doi: 10.1097/j.pain.0000000000000659.
    1. Wang H, et al. Effect of morphine and pregabalin compared with diphenhydramine hydrochloride and placebo on hyperalgesia and allodynia induced by intradermal capsaicin in healthy male subjects. J Pain. 2008;9(12):1088–1095. doi: 10.1016/j.jpain.2008.05.013.
    1. Wallace MS, Schulteis G. Effect of chronic oral gabapentin on capsaicin-induced pain and hyperalgesia: a double-blind, placebo-controlled, crossover study. Clin J Pain. 2008;24(6):544–549. doi: 10.1097/AJP.0b013e3181673b93.
    1. Wellek S, Blettner M. On the proper use of the crossover design in clinical trials: part 18 of a series on evaluation of scientific publications. Dtsch Arztebl Int. 2012;109(15):276–281.
    1. Pharmaceuticals, V. Trental: Labeling-Package Insert, Reference ID: 3873773 2016; Available from: .
    1. Keränen A, Nykänen S, Taskinen J. Pharmacokinetics and side-effects of clonidine. Eur J Clin Pharmacol. 1978;13(2):97–101. doi: 10.1007/BF00609752.
    1. Hunyor SN, et al. Effects of clonidine withdrawal: possible mechanisms and suggestions for management. Br Med J. 1973;2(5860):209–211. doi: 10.1136/bmj.2.5860.209.
    1. Gewandter JS, et al. Research designs for proof-of-concept chronic pain clinical trials: IMMPACT recommendations. Pain. 2014;155(9):1683–1695. doi: 10.1016/j.pain.2014.05.025.
    1. Senn SS. Cross-over trials in clinical research. Hoboken: Wiley; 2002.
    1. Ward A, Clissold SP. Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs. 1987;34(1):50–97. doi: 10.2165/00003495-198734010-00003.
    1. Raja SN, et al. Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology. 2002;59(7):1015–1021. doi: 10.1212/WNL.59.7.1015.
    1. Jenkins TM, et al. Efficient assessment of efficacy in post-traumatic peripheral neuropathic pain patients: pregabalin in a randomized, placebo-controlled, crossover study. J Pain Res. 2012;5:243–250.
    1. Gilron I, et al. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial. Lancet. 2009;374(9697):1252–1261. doi: 10.1016/S0140-6736(09)61081-3.
    1. Katz J, Finnerup NB, Dworkin RH. Clinical trial outcome in neuropathic pain: relationship to study characteristics. Neurology. 2008;70(4):263–272. doi: 10.1212/01.wnl.0000275528.01263.6c.
    1. Wallace MS, et al. A randomized, double-blind, placebo-controlled trial of a glycine antagonist in neuropathic pain. Neurology. 2002;59(11):1694–1700. doi: 10.1212/01.WNL.0000036273.98213.34.
    1. Mehta P, et al. Outcome measures in randomized-controlled trials of neuropathic pain conditions: a systematic review of systematic reviews and recommendations for practice. Clin J Pain. 2015;31(2):169–176. doi: 10.1097/AJP.0000000000000088.
    1. Younger J, McCue R, Mackey S. Pain outcomes: a brief review of instruments and techniques. Curr Pain Headache Rep. 2009;13(1):39–43. doi: 10.1007/s11916-009-0009-x.
    1. Russo MA, Santarelli DM. A novel compound analgesic cream (ketamine, pentoxifylline, clonidine, DMSO) for complex regional pain syndrome patients. Pain Pract. 2016;16(1):E14–E20. doi: 10.1111/papr.12404.
    1. Lim TK, et al. Peripheral nerve injury induces persistent vascular dysfunction and endoneurial hypoxia, contributing to the genesis of neuropathic pain. J Neurosci. 2015;35(8):3346–3359. doi: 10.1523/JNEUROSCI.4040-14.2015.
    1. Kirchmair R, et al. Therapeutic angiogenesis inhibits or rescues chemotherapy-induced peripheral neuropathy: taxol-and thalidomide-induced injury of vasa nervorum is ameliorated by VEGF. Mol Ther. 2007;15(1):69–75. doi: 10.1038/sj.mt.6300019.
    1. Fulas OA, et al. Topical combination of meldonium and N-acetyl cysteine relieves allodynia in rat models of CRPS-1 and peripheral neuropathic pain by enhancing NO-mediated tissue oxygenation. J Neurochem. 2020;152(5):570–584. doi: 10.1111/jnc.14943.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다